Compare VMAR & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMAR | XRTX |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 2.7M |
| IPO Year | 2020 | 2018 |
| Metric | VMAR | XRTX |
|---|---|---|
| Price | $2.04 | $2.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.6K | ★ 42.4K |
| Earning Date | 04-10-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.35 |
| 52 Week High | $8.88 | $2.34 |
| Indicator | VMAR | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 86.64 |
| Support Level | $1.92 | $0.75 |
| Resistance Level | $2.78 | N/A |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 37.98 | 89.47 |
Vision Marine Technologies Inc designs and manufactures electric outboard powertrain systems, power boats, related technology, and rents electric boats. Its models include Bruce 22, Fantail 217, VX Electric Pontoon, Volt 180, Phantom, and others. The company provides goods and services for the recreational boating market and focuses on electric outboard powertrain systems, electric power boats, and the renting of electric boats through its subsidiary. It sells boats, parts, and accessories and offers services related to recreational boating, including boats with internal combustion engines and electric propulsion. The company operates in two reportable segments, the sale of electric boats and the rental of electric boats, and generates a substantial portion of its revenue from the USA.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.